Cargando…

Under-reported relationship: a comparative study of pharmaceutical industry and patient organisation payment disclosures in the UK (2012–2016)

OBJECTIVES: To examine the under-reporting of pharmaceutical company payments to patient organisations by donors and recipients. DESIGN: Comparative descriptive analysis of payments disclosed on drug company and charity regulator websites. SETTING: UK. PARTICIPANTS: 87 donors (drug companies) and 42...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ozieranski, Piotr, Csanádi, Marcell, Rickard, Emily, Mulinari, Shai
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2020
Materias:	Health Policy
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7511620/ https://www.ncbi.nlm.nih.gov/pubmed/32950962 http://dx.doi.org/10.1136/bmjopen-2020-037351

Ejemplares similares

Disclosure of payments by pharmaceutical companies to healthcare professionals in the UK: analysis of the Association of the British Pharmaceutical Industry’s Disclosure UK database, 2015 and 2016 cohorts
por: Mulinari, Shai, et al.
Publicado: (2018)

Analysis of Pharmaceutical Industry Payments to UK Health Care Organizations in 2015
por: Ozieranski, Piotr, et al.
Publicado: (2019)

International comparison of pharmaceutical industry payment disclosures in the UK and Japan: implications for self-regulation, public regulation, and transparency
por: Ozieranski, Piotr, et al.
Publicado: (2023)

Pharmaceutical industry payments to NHS trusts in England: A four-year analysis of the Disclosure UK database
por: Ozieranski, Piotr, et al.
Publicado: (2023)

Accessibility and quality of drug company disclosures of payments to healthcare professionals and organisations in 37 countries: a European policy review
por: Ozieranski, Piotr, et al.
Publicado: (2021)

Exposing drug industry funding of UK patient organisations
por: Ozieranski, Piotr, et al.
Publicado: (2019)

Disclosure of Pharmaceutical Industry Funding of Patient Organisations in Nordic Countries: Can Industry Self-Regulation Deliver on its Transparency Promise?
por: Pashley, Dylan, et al.
Publicado: (2022)

Five years of pharmaceutical industry funding of patient organisations in Sweden: Cross-sectional study of companies, patient organisations and drugs
por: Mulinari, Shai, et al.
Publicado: (2020)

Comparing pharmaceutical company payments in the four UK countries: a cross-sectional and social network analysis
por: Rickard, Emily, et al.
Publicado: (2023)

Voluntary disclosures of payments from pharmaceutical companies to healthcare professionals in Germany: a descriptive study of disclosures in 2015 and 2016
por: Stoll, Marlene, et al.
Publicado: (2020)

Sunshine Policies and Murky Shadows in Europe: Disclosure of Pharmaceutical Industry Payments to Health Professionals in Nine European Countries
por: Fabbri, Alice, et al.
Publicado: (2018)

Mandatory Disclosure of Pharmaceutical Industry-Funded Events for Health Professionals
por: Robertson, Jane, et al.
Publicado: (2009)

A hidden web of policy influence: The pharmaceutical industry’s engagement with UK’s All-Party Parliamentary Groups
por: Rickard, Emily, et al.
Publicado: (2021)

Drug company payments to General Practices in England: Cross-sectional and social network analysis
por: Saghy, Eszter, et al.
Publicado: (2021)

Tip of the Iceberg? Country- and Company-Level Analysis of Drug Company Payments for Research and Development in Europe
por: Ozieranski, Piotr, et al.
Publicado: (2022)

Physicians’ attitudes towards disclosure of payments from pharmaceutical companies in a nationwide voluntary transparency database: a cross-sectional survey
por: Stoll, Marlene, et al.
Publicado: (2022)

Industry funding of patient organisations in the UK: a retrospective study of commercial determinants, funding concentration and disease prevalence
por: Gentilini, Arianna, et al.
Publicado: (2023)

Complaints, Complainants, and Rulings Regarding Drug Promotion in the United Kingdom and Sweden 2004–2012: A Quantitative and Qualitative Study of Pharmaceutical Industry Self-Regulation
por: Zetterqvist, Anna V., et al.
Publicado: (2015)

National patient groups in Canada and their disclosure of relationships with pharmaceutical companies: a cross-sectional study
por: Lexchin, Joel, et al.
Publicado: (2022)

Misleading Advertising for Antidepressants in Sweden: A Failure of Pharmaceutical Industry Self-Regulation
por: Zetterqvist, Anna V., et al.
Publicado: (2013)

Impact of US industry payment disclosure laws on payments to surgeons: a natural experiment
por: Rhee, Taeho Greg, et al.
Publicado: (2020)

Soft Targets: Nurses and the Pharmaceutical Industry
por: Jutel, Annemarie, et al.
Publicado: (2008)

Pharmaceutical Industry Off-label Promotion and Self-regulation: A Document Analysis of Off-label Promotion Rulings by the United Kingdom Prescription Medicines Code of Practice Authority 2003–2012
por: Vilhelmsson, Andreas, et al.
Publicado: (2016)

US Nationwide Disclosure of Industry Payments and Public Trust in Physicians
por: Kanter, Genevieve P., et al.
Publicado: (2019)

BBMRI-ERIC as a resource for pharmaceutical and life science industries: the development of biobank-based Expert Centres
por: van Ommen, Gert-Jan B, et al.
Publicado: (2015)

A cross-sectional study of all clinicians’ conflict of interest disclosures to NHS hospital employers in England 2015-2016
por: Feldman, Harriet Ruth, et al.
Publicado: (2018)

Fundamental Reform of Payment for Adult Primary Care: Comprehensive Payment for Comprehensive Care
por: Goroll, Allan H., et al.
Publicado: (2007)

The alcohol industry, charities and policy influence in the UK
por: Lyness, Sarah M, et al.
Publicado: (2014)

Pharmaceutical payments to Japanese certified hematologists: a retrospective analysis of personal payments from pharmaceutical companies between 2016 and 2019
por: Kusumi, Eiji, et al.
Publicado: (2022)

Inter-organisational communication networks in healthcare: centralised versus decentralised approaches
por: Pirnejad, Habibollah, et al.
Publicado: (2007)

Pharmaceutical industry payments and assisted reproduction in Australia: a retrospective observational study
por: Karanges, Emily Aspasia, et al.
Publicado: (2021)

Characteristics of physicians receiving large payments from pharmaceutical companies and the accuracy of their disclosures in publications: an observational study
por: Norris, Susan L, et al.
Publicado: (2012)

Industry views of the UK Soft Drinks Industry Levy: a thematic analysis of elite interviews with food and drink industry professionals, 2018–2020
por: Jones, Catrin P, et al.
Publicado: (2023)

Global Budget Payment: Proposing the CAP Framework
por: Chen, Bradley, et al.
Publicado: (2016)

Factors affecting adherence to non-pharmaceutical interventions for COVID-19 infections in the first year of the pandemic in the UK
por: Ding, Xuejie, et al.
Publicado: (2021)

Contemporary Analysis of Inconsistencies Between Physician-reported Disclosures at the AAOS Annual Meeting and Industry-reported Financial Disclosures in the Open Payments Database
por: Bovonratwet, Patawut, et al.
Publicado: (2022)

Reactions of industry and associated organisations to the announcement of the UK Soft Drinks Industry Levy: longitudinal thematic analysis of UK media articles, 2016-18
por: Penney, Tarra L., et al.
Publicado: (2023)

Mining Open Payments Data: Analysis of Industry Payments to Thoracic Surgeons From 2014-2016
por: Na, Xu, et al.
Publicado: (2018)

Evaluation of Pharmaceutical Company Payments and Conflict of Interest Disclosures Among Oncology Clinical Practice Guideline Authors in Japan
por: Saito, Hiroaki, et al.
Publicado: (2019)

Pharmaceutical lobbying and pandemic stockpiling of Tamiflu: a qualitative study of arguments and tactics
por: Vilhelmsson, Andreas, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_odqdgqsvdvsdjc209mdg5t5lhc